Vertex Interest Income from 2010 to 2024

VRTX Stock

USD 464.56 2.51 0.54%

Vertex Pharmaceuticals Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2024. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

156.5 M

Current Value

132.2 M

Quarterly Volatility

69.9 M

Covid

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Interest Income Growth Pattern

Below is the plot of the Interest Income of Vertex Pharmaceuticals over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Vertex Pharmaceuticals' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Vertex Interest Income Regression Statistics

	Arithmetic Mean	144,884,400
	Geometric Mean	77,599,411
	Coefficient Of Variation	137.88
	Mean Deviation	129,382,160
	Median	84,206,000
	Standard Deviation	199,760,889
	Sample Variance	39904.4T
	Range	640.5M
	R-Value	0.55
	Mean Square Error	30190.5T
	R-Squared	0.30
	Significance	0.04
	Slope	24,362,214
	Total Sum of Squares	558661.8T

Vertex Interest Income History

	2024	645.4 M
	2023	614.7 M
	2022	144.6 M
	2021	4.9 M
	2020	22.2 M
	2019	63.7 M
	2018	33.5 M

Other Fundumenentals of Vertex Pharmaceuticals

Net Interest Income

Vertex Pharmaceuticals Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Common Stock	Long Term Debt	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.98	0.94	0.99	1.0	-0.07	0.98	0.99	0.37	0.04	0.23	0.93	0.2	0.83	0.44	0.99	0.08	0.66	-0.55	0.78	0.79	0.93	0.92	0.78
Total Stockholder Equity	1.0		-0.98	0.95	0.98	1.0	-0.08	0.97	0.99	0.35	0.01	0.22	0.92	0.21	0.84	0.44	1.0	0.06	0.66	-0.56	0.79	0.79	0.94	0.92	0.78
Net Debt	-0.98	-0.98		-0.94	-0.96	-0.99	0.1	-0.95	-0.99	-0.34	0.0	-0.13	-0.89	-0.24	-0.84	-0.45	-0.99	0.02	-0.66	0.55	-0.79	-0.68	-0.96	-0.97	-0.69
Retained Earnings	0.94	0.95	-0.94		0.89	0.94	-0.07	0.93	0.93	0.07	-0.14	0.12	0.79	0.1	0.76	0.58	0.94	-0.07	0.44	-0.35	0.63	0.81	0.9	0.89	0.79
Total Liab	0.99	0.98	-0.96	0.89		0.99	-0.02	0.98	0.98	0.47	0.12	0.27	0.94	0.19	0.81	0.43	0.97	0.17	0.68	-0.55	0.78	0.78	0.91	0.9	0.76
Total Current Assets	1.0	1.0	-0.99	0.94	0.99		-0.08	0.98	0.99	0.37	0.03	0.21	0.93	0.21	0.83	0.44	1.0	0.07	0.65	-0.56	0.78	0.76	0.94	0.94	0.75
Short Term Debt	-0.07	-0.08	0.1	-0.07	-0.02	-0.08		0.02	-0.07	0.02	-0.13	-0.3	-0.03	-0.15	-0.28	0.12	-0.1	-0.05	-0.2	0.24	-0.17	0.09	-0.11	-0.11	0.03
Accounts Payable	0.98	0.97	-0.95	0.93	0.98	0.98	0.02		0.96	0.38	0.1	0.23	0.92	0.18	0.72	0.47	0.96	0.18	0.57	-0.46	0.69	0.82	0.9	0.89	0.8
Net Receivables	0.99	0.99	-0.99	0.93	0.98	0.99	-0.07	0.96		0.37	0.02	0.18	0.91	0.22	0.86	0.45	0.99	0.03	0.67	-0.55	0.8	0.72	0.94	0.94	0.71
Common Stock	0.37	0.35	-0.34	0.07	0.47	0.37	0.02	0.38	0.37		0.6	0.51	0.56	0.28	0.34	-0.1	0.36	0.42	0.72	-0.61	0.48	0.13	0.4	0.38	0.23
Long Term Debt	0.04	0.01	0.0	-0.14	0.12	0.03	-0.13	0.1	0.02	0.6		0.41	0.21	-0.05	0.02	-0.1	0.01	0.87	0.31	-0.23	0.0	-0.04	0.11	0.09	0.06
Short Term Investments	0.23	0.22	-0.13	0.12	0.27	0.21	-0.3	0.23	0.18	0.51	0.41		0.28	-0.06	0.29	0.02	0.21	0.34	0.21	-0.25	0.09	0.25	0.22	0.17	0.27
Property Plant Equipment	0.93	0.92	-0.89	0.79	0.94	0.93	-0.03	0.92	0.91	0.56	0.21	0.28		0.2	0.73	0.16	0.93	0.29	0.77	-0.75	0.79	0.73	0.84	0.83	0.72
Current Deferred Revenue	0.2	0.21	-0.24	0.1	0.19	0.21	-0.15	0.18	0.22	0.28	-0.05	-0.06	0.2		0.06	-0.2	0.25	-0.14	0.43	-0.34	0.55	0.03	0.21	0.18	0.04
Good Will	0.83	0.84	-0.84	0.76	0.81	0.83	-0.28	0.72	0.86	0.34	0.02	0.29	0.73	0.06		0.4	0.83	-0.07	0.68	-0.55	0.76	0.49	0.83	0.81	0.5
Intangible Assets	0.44	0.44	-0.45	0.58	0.43	0.44	0.12	0.47	0.45	-0.1	-0.1	0.02	0.16	-0.2	0.4		0.4	-0.23	-0.06	0.41	0.07	0.41	0.54	0.54	0.5
Net Tangible Assets	0.99	1.0	-0.99	0.94	0.97	1.0	-0.1	0.96	0.99	0.36	0.01	0.21	0.93	0.25	0.83	0.4		0.05	0.68	-0.59	0.8	0.76	0.94	0.93	0.75
Long Term Debt Total	0.08	0.06	0.02	-0.07	0.17	0.07	-0.05	0.18	0.03	0.42	0.87	0.34	0.29	-0.14	-0.07	-0.23	0.05		0.18	-0.22	-0.05	0.19	-0.01	-0.02	0.16
Capital Surpluse	0.66	0.66	-0.66	0.44	0.68	0.65	-0.2	0.57	0.67	0.72	0.31	0.21	0.77	0.43	0.68	-0.06	0.68	0.18		-0.86	0.88	0.37	0.68	0.64	0.47
Deferred Long Term Liab	-0.55	-0.56	0.55	-0.35	-0.55	-0.56	0.24	-0.46	-0.55	-0.61	-0.23	-0.25	-0.75	-0.34	-0.55	0.41	-0.59	-0.22	-0.86		-0.73	-0.28	-0.52	-0.5	-0.3
Short Long Term Debt	0.78	0.79	-0.79	0.63	0.78	0.78	-0.17	0.69	0.8	0.48	0.0	0.09	0.79	0.55	0.76	0.07	0.8	-0.05	0.88	-0.73		0.48	0.73	0.7	0.49
Long Term Investments	0.79	0.79	-0.68	0.81	0.78	0.76	0.09	0.82	0.72	0.13	-0.04	0.25	0.73	0.03	0.49	0.41	0.76	0.19	0.37	-0.28	0.48		0.65	0.59	0.95
Net Invested Capital	0.93	0.94	-0.96	0.9	0.91	0.94	-0.11	0.9	0.94	0.4	0.11	0.22	0.84	0.21	0.83	0.54	0.94	-0.01	0.68	-0.52	0.73	0.65		0.99	0.73
Net Working Capital	0.92	0.92	-0.97	0.89	0.9	0.94	-0.11	0.89	0.94	0.38	0.09	0.17	0.83	0.18	0.81	0.54	0.93	-0.02	0.64	-0.5	0.7	0.59	0.99		0.66
Capital Stock	0.78	0.78	-0.69	0.79	0.76	0.75	0.03	0.8	0.71	0.23	0.06	0.27	0.72	0.04	0.5	0.5	0.75	0.16	0.47	-0.3	0.49	0.95	0.73	0.66

Click cells to compare fundamentals

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	614.7 M	645.4 M
Net Interest Income	570.6 M	599.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Interest Income from 2010 to 2024

Latest Vertex Pharmaceuticals' Interest Income Growth Pattern

Vertex Interest Income Regression Statistics

Vertex Interest Income History

Other Fundumenentals of Vertex Pharmaceuticals

Vertex Pharmaceuticals Interest Income component correlations

About Vertex Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY